Related Experiment Video
Updated: Mar 19, 2026
Manipulation of Ploidy in Caenorhabditis elegans
Published on: March 15, 2018
Polypill: quo vadis?
Francesca Muscente1, Raffaele De Caterina
1aInstitute of Cardiology and Center of Excellence on Aging, G. d'Annunzio University - Chieti-Pescara, Chieti bG. Monasterio Foundation, Pisa, Italy.
Insights
Cardiovascular disease (CVD) prevention strategies can be improved with polypills, which combine multiple medications. These pills may enhance treatment adherence and accessibility, particularly in low-income countries, though long-term effects require further study.
Area of Science:
- Cardiology
- Public Health
- Pharmacology
Background:
- Cardiovascular disease (CVD) remains the leading global cause of mortality.
- Increasing CVD incidence in low- and middle-income countries is linked to health policy, medication access, and patient adherence issues.
- Polypills (fixed-dose combination pills) offer a potential strategy to improve CVD prevention by combining multiple drugs.
Purpose of the Study:
- To evaluate the potential of polypills in enhancing cardiovascular disease prevention strategies.
- To assess the benefits and limitations of polypills regarding cost, accessibility, and patient adherence.
- To explore optimal patient selection for polypill therapy.
Main Methods:
- Review of clinical trials on fixed-dose combination pills for CVD risk factors.
- Analysis of projected improvements in cardiovascular endpoints based on risk factor reduction.
- Discussion of challenges including long-term adherence, cost-effectiveness, and population-wide application.
Main Results:
- Clinical trials indicate polypills are well-tolerated and effectively reduce cardiovascular risk factors like blood pressure and LDL cholesterol.
- Projected improvements in major cardiovascular endpoints range from 60-70% with polypill use.
- Uncertainty persists regarding hard endpoints, long-term adherence, cost-effectiveness, and the 'medicalization' of asymptomatic individuals.
Conclusions:
- Polypills show promise for improving CVD prevention, especially in resource-limited settings, by potentially increasing adherence and accessibility.
- Targeting specific high-risk populations, possibly identified through combined risk scores (e.g., Coronary Artery Calcium Score and Framingham Risk Score), may be more practical than treating all individuals over 50.
- Further research and ongoing trials are necessary to resolve current debates on polypill efficacy, cost-effectiveness, and long-term outcomes.
Abstract:
Cardiovascular disease (CVD) is still the leading cause of death worldwide. The overall growth of this epidemic during the last decade is largely because of the increasing incidence of CVD in low and middle-income countries, where inadequate health policies, poor availability, and lack of affordable medications, as well as poor patient adherence to treatment all limit the efficacy of cardiovascular prevention strategies. Complementary to a promotion of healthy lifestyles, a fixed dose combination or a 'polypill,' containing two or more drugs addressed at controlling various risk factors, might reduce costs and improve patient accessibility and adherence to treatment. As of now, several clinical trials have shown that combination pills are well tolerated and decrease risk factors for CVD, with a projected improvement of end points by as much as 60-70% by reducing blood pressure and low-density lipoprotein cholesterol. However, uncertainty remains about changes of hard end points, long-term adherence, cost-effectiveness and the 'medicalization' of asymptomatic individuals who account for a large percentage of the world population. Because cardiovascular risk increases significantly for patients aged more than 50 years, it has been proposed to use a polypill to treat specifically all such patients. However, approach to be neither practical nor cost-effective, because it involves a large number of patients at low risk. Some investigators have suggested to incorporate the Coronary Artery Calcium Score with the Framingham Risk Score to identify a suitable target population of patients benefitting most from the polypill. Trials in progress will shed light on several issues currently debated and unresolved.
Related Concept Videos
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:18Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
01:21Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...